Alzheimer’s disease (AD) is a neurological disorder of unknown origin that is characterized by a progressive loss of memory and learned behavior. Patients with Alzheimers are also likely to experience depression, agitation, and appetite loss, among other symptoms. Over 4.5 million Americans are estimated to be afflicted with the disease. No approved treatments or medications are available to modulate the progression of AD, and few pharmaceuticals effectively treat symptoms of the disease. Preclinical data shows the potential of cannabinoids to moderate the progression of AD while clinical data demonstrates that these compounds can provide symptom relief.